1.
Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
2.
3.
4.
5.
6.
7.
8.
9.
Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
Table1_Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking.DOCX
The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis
datasheet1_Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.docx
Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
DataSheet1_Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care.PDF
Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study